Biocon shares jump 7% on strong Q4, dividend declaration
Biocon declared a dividend of ₹1.50 per share for FY23, which includes payout on account of one-time exceptional gains arising from partial monetisation of its holdings in Syngene
Biocon declared a dividend of ₹1.50 per share for FY23, which includes payout on account of one-time exceptional gains arising from partial monetisation of its holdings in Syngene
The board of India's second-largest software services firm has appointed D. Sundaram as the lead independent director with effect from March 23.
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
Biocon shares declined as much as 2.4% to ₹262.40 on Wednesday, hitting its lowest level since November 2019.
Falguni Nayar of Nykaa is 2nd richest, with net worth of ₹57,520 cr; she’s also India's richest self-made woman, shows 'Leading Wealthy Women 2021' report by Hurun India, Kotak Private Banking
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
Resurgence of interest and new technologies bring a huge opportunity for the vaccine development field, says Biocon CMD Kiran Mazumdar-Shaw.
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
The Biocon executive chairperson said curfews and lockdowns makes no sense as they have not proven helpful in curbing this pandemic.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.